The people, processes, and skills that built the business are rarely the same ones required to exit.
The company you run every day may not translate cleanly to how buyers, investors, or partners see it from the outside.


Undervaluation is usually a perception problem before it becomes a performance problem. Buyers form opinions long before diligence begins, and those opinions are hard to outrun under time pressure.
A clear, credible commercial story is an asset. It reduces friction, shortens cycles, and protects value. Speed matters because exits operate on fixed timelines, even when businesses don’t.
Our framework changes outcomes
Legacy DNA has helped healthtech and pharmacy companies:
We consistently focus on valuation drivers, not surface metrics. We’ve guided four successful exits. Our executives have doctorate-level strategic rigor paired with operator experience, and we leverage a deep understanding of commercialization, regulatory complexity, and buyer psychology.
We've helped leadership teams navigate four Successful exits by turning strong businesses into stories buyers recognize, trust, and value.
This is a private, 10-question diagnostic survey that clarifies how your company currently presents to buyers and identifies potential risks. No benchmarking. No judgment. Just insight into your readiness.
Get my Exit Readiness Scorecard

We offer a strategic discussion with one of our senior executives. We’ll interpret the scorecard's findings or your own analysis of the situation and determine if it’s time to take action.
Book my Exit Readiness Diagnostic consultation